Skip to search formSkip to main content

BMS 181339

Known as: BMS-181339 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
A Phase II study of paclitaxel in patients with primary advanced or metastatic breast cancer was conducted by a cooperative study… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
1997
1997
BACKGROUND Paclitaxel (BMS-181339: Taxol) is a promising agent against previously treated breast cancer. The antitumor activity… Expand
Is this relevant?
1996
1996
A phase II study of Paclitaxel in patients with ovarian cancer by 3-hour intravenous infusion was undertaken by a cooperative… Expand
Is this relevant?
Review
1996
Review
1996
We conducted a multi-institutional (11 facilities), early phase II study of BMS-181339 (paclitaxel), a novel anti-cancer drug… Expand
Is this relevant?
1994
1994
We conducted a multicenter Phase II study of BMS-181339 in patients with ovarian cancer. The facilities participating were 23 in… Expand
Is this relevant?